Celldex Therapeutics, Inc. (CLDX) Stock Price & Analysis
Celldex Therapeutics, Inc. (CLDX) rose 3.64% to USD 29.6 as of June 10, 2026 at 02:13 UTC, according to Nexqual real-time market data.
CLDX last closed at USD 28.56; the session ranged USD 28.54–29.73 on volume of 591,302 shares. Market capitalization is $2.32B, with a 52-week range of USD 19.52–35.79 (NCM). Source: Nexqual, June 10, 2026 at 02:13 UTC.
Key Statistics (as of June 10, 2026 at 02:13 UTC)
| Price | USD 29.6 |
|---|---|
| Change | ▲ 3.64% (up) |
| Previous Close | USD 28.56 |
| Open | USD 29.03 |
| Day Range | USD 28.54 – 29.73 |
| 52-Week Range | USD 19.52 – 35.79 |
| Volume | 591,302 shares |
| Market Cap | $2.32B |
| Exchange | NCM |
Technical Analysis (CLDX)
Nexqual's technical model rates CLDX "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 02:13 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 40.94 (neutral) |
| vs SMA50 | Below (USD 31.98) |
| MACD | -0.82 (negative) |
Analyst Ratings (CLDX)
Wall Street analysts rate CLDX "None" based on 14 analysts, with a mean price target of USD 58.43 (range USD 38–90), per Nexqual as of June 10, 2026 at 02:13 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 14 |
| Mean Target | USD 58.43 |
| High Target | USD 90 |
| Low Target | USD 38 |
| Buy / Hold / Sell | 14 / 1 / 0 |
Earnings (CLDX)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -1.06 |
| Revenue Estimate | $858,900 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -1.18 vs est -1.13 ▼ miss |
| 2025-12-31 | USD -1.22 vs est -1 ▼ miss |
| 2025-09-30 | USD -1.01 vs est -0.89 ▼ miss |
| 2025-06-30 | USD -0.85 vs est -0.84 ▼ miss |
Source: Nexqual, June 10, 2026 at 02:13 UTC.
Financials & Fundamentals (CLDX)
| Total Revenue | $865,000 |
|---|---|
| Revenue Growth (YoY) | -97.80% |
| Gross Margin | +0.00% |
| Operating Margin | -562900.00% |
| Profit Margin | +0.00% |
| ROE | -48.94% |
| Debt / Equity | 0.42 |
| Current Ratio | 8.92 |
| Total Cash | $451.46M |
| Total Debt | $1.91M |
| Free Cash Flow | $-126.27M |
Source: Nexqual, June 10, 2026 at 02:13 UTC.
Financial Health Score (CLDX)
Nexqual rates Celldex Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:13 UTC.
| Growth | Critical — Revenue -78% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $451M cash vs $2M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$126M, burning cash |
| Efficiency | Critical — ROE -49%, ROA -30.9% |
Ownership (CLDX)
| Insider Ownership | +0.27% |
|---|---|
| Institutional Ownership | +94.90% |
| Shares Outstanding | 78.49M |
| Float | 72.46M |
| Short % of Float | +10.80% |
Source: Nexqual, June 10, 2026 at 02:13 UTC.
Leadership (CLDX)
Celldex Therapeutics, Inc. is led by Anthony S. Marucci (age 63), Founder, President, CEO & Director, per Nexqual as of June 10, 2026 at 02:13 UTC.
| Founder, President, CEO & Director | Anthony S. Marucci (age 63) |
|---|---|
| Founder, Chief Scientific Officer & Executive VP | Tibor Keler (age 66) |
| Senior VP, CFO, Secretary & Treasurer | Sam Martin (age 54) |
| Chief Product Development Officer & Senior VP | Elizabeth Crowley (age 53) |
| Senior Vice President of Regulatory Affairs | Margo Heath-Chiozzi (age 68) |
Major Backers & Investors (CLDX)
Notable institutional backers of Celldex Therapeutics, Inc. include Wellington Management, Kynam Capital Management, LP, FMR, LLC, according to Nexqual as of June 10, 2026 at 02:13 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Wellington Management | 10.91% |
| Kynam Capital Management, LP | 7.44% |
| FMR, LLC | 4.78% |
| Point72 Asset Management, L.P. | 4.11% |
| Commodore Capital Lp | 3.44% |
| Price (T.Rowe) Associates Inc | 2.66% |
| Eversept Partners, LP | 2.28% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 14.88% |
| BlackRock | 9.92% |
| State Street | 5.29% |
Source: Nexqual, June 10, 2026 at 02:13 UTC.
From Celldex Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-25)
Key Strengths & Strategy (as disclosed to the SEC)
- This approach allows us to maximize the overall value of our technology and product portfolio while best ensuring the expeditious development of each individual product.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | USD 21.84 | ▲ 1.3% |
| EXEL | Exelixis, Inc. | USD 52.99 | ▲ 0.55% |
| HALO | Halozyme Therapeutics, Inc. | USD 71.48 | ▼ 0.07% |
| AGEN | Agenus Inc. | USD 3.11 | ▼ 3.72% |
| AGIO | Agios Pharmaceuticals, Inc. | USD 28.14 | ▼ 0.53% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:13 UTC. This page is informational and not investment advice.